Report on the risk assessment of methyl 1-(2-phenylethyl)-4-[phenyl(propanoyl)amino]piperidine-4-carboxylate (carfentanil) in the framework of the Council Decision on new psychoactive substances

Series type: Risk assessments

Summary

This publication presents the data and findings of the risk assessment on methyl 1-(2-phenylethyl)-4-[phenyl(propanoyl)amino]piperidine-4-carboxylate (carfentanil), carried out by the extended Scientific Committee of the EMCDDA on 7-8 November 2017. In March 2018, at its 61st regular session, the Commission on Narcotic Drugs (CND) decided to place carfentanil in Schedule I and Schedule IV of the Single Convention on Narcotic Drugs of 1961 based on a recommendation by the World Health Organization. This recommendation was substantially supported by European data provided by the EMCDDA.

Download as PDF

Table of contents

  • Foreword
  • EMCDDA actions on monitoring and responding to new drugs
  • Europol–EMCDDA Joint Report on carfentanil (methyl 1-(2-phenylethyl)-4-[phenyl(propanoyl)amino]piperidine-4-carboxylate) — a summary
  • Risk Assessment Report on a new psychoactive substance: methyl 1-(2-phenylethyl)-4-[phenyl(propanoyl)amino]piperidine-4-carboxylate (carfentanil)
  • Technical report on methyl 1-(2-phenylethyl)-4-[phenyl(propanoyl)amino]piperidine-4-carboxylate (carfentanil)
  • Participants of the risk assessment meeting, 7-8 November 2017

Main subject:

NPS

Cover of the risk assessment
Pages: 
105
Price: 
free
ISBN: 
978-92-9497-302-3
ISSN: 
1725-4493
Pub. DOI: 
10.2810/411341
Catalog Number: 
TD-AK-18-004-EN-N
Loading